T-CURX provides a non‑viral CAR‑T platform that uses T‑cell‑targeted lipid nanoparticles to deliver Sleeping Beauty transposon vectors, enabling stable in vivo expression of chimeric antigen receptors directly at the bedside. By eliminating viral vector production and ex vivo cell manufacturing, the technology reduces cost, complexity, and immunogenicity, making autologous CAR‑T therapies more accessible for oncology indications such as AML, CLL, and other hematologic and solid‑tumor targets.
Funding
Funding not disclosed
Founders
Product
Problem
Current autologous CAR‑T cell therapies rely on ex vivo manufacturing using viral vectors, which is costly, logistically complex, and limited to specialized centers, restricting patient access and driving high treatment prices.
Solution
T‑CURX develops a non‑viral CAR‑T platform that delivers Sleeping Beauty transposon vectors via T‑cell‑targeted lipid nanoparticles (LNPs). This approach enables stable, in vivo expression of chimeric antigen receptors directly after bedside administration, eliminating the need for viral production and centralized cell processing. The technology supports both in vivo CAR‑T generation and rapid bedside‑manufactured CAR‑T products, aiming to lower manufacturing costs and expand availability. T‑CURX is advancing a pipeline of clinical candidates targeting acute myeloid leukemia, chronic lymphocytic leukemia, and additional antigens shared across hematologic and solid‑tumor indications. By combining LNP delivery with a transposon system, the platform offers durable CAR expression without the immunogenicity associated with viral vectors.
Target Audience
Primary customers are pharmaceutical and biotech companies developing cell‑based immunotherapies, as well as clinical research organizations seeking a cost‑effective, scalable method to produce autologous CAR‑T cells for oncology trials.
Features
- Lipid‑nanoparticle (LNP) formulation engineered for selective uptake by patient T cells in peripheral blood
- Sleeping Beauty transposon system providing stable genomic integration of CAR constructs for long‑term expression
- Non‑viral, virus‑free manufacturing eliminates viral vector production, reducing immunogenicity and regulatory complexity
- Capability for bedside administration, enabling rapid, point‑of‑care generation of autologous CAR‑T cells
- Pipeline includes candidates for AML, CLL, and cross‑entity targets applicable to both hematologic malignancies and solid tumors
- Scalable platform compatible with multiple CAR designs and antigen targets